Antoinette D I van Asselt (Antoinette van Asselt, Thea van Asselt)

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 20

Top Topics

Respiratory Tract

Ulcerative Colitis

Systematic Review

Top Venues

PharmacoEconomics

Health economics review

Journal of medical Internet research

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Leslie R Zwerwer, Jan Andreas Kloka, Simon van der Pol, Maarten Jacobus Postma, Kai Zacharowski, Antoinette D I van Asselt, Benjamin Friedrichson
Mechanical ventilation as a major driver of COVID-19 hospitalization costs: a costing study in a German setting. Health economics review 14 (1) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Leslie R Zwerwer, Jan Andreas Kloka, Simon van der Pol, Maarten Jacobus Postma, Kai Zacharowski, Antoinette D I van Asselt, Benjamin Friedrichson
Mechanical ventilation as a major driver of COVID-19 hospitalization costs: a costing study in a German setting. Health economics review 14 (1) (2024)
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten Jacobus Postma, Antoinette D I van Asselt
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. PharmacoEconomics 42 (6) (2024)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2023)
Simon van der Pol, Danielle E M C Jansen, Alexander W Friedrich, Christopher C Butler, Theo J M Verheij, Alex W Friedrich, Maarten J Postma, Antoinette D I van Asselt
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance. PharmacoEconomics 40 (8) (2022)
Simon van der Pol, Paula Rojas Garcia, Maarten Jacobus Postma, Fernando Antoñanzas Villar, Antoinette D I van Asselt
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. PharmacoEconomics 39 (12) (2021)
Anna Nicolet, Antoinette D I van Asselt, Karin M Vermeulen, Paul F M Krabbe
Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands. PloS one 15 (7) (2020)
Willem J A Witlox, Sabine E Grimm, Rob Riemsma, Nigel Armstrong, Steve Ryder, Steven Duffy, Vanesa Huertas Carrera, Pawel Posadzki, Gillian Worthy, Xavier G L V Pouwels, Bram L T Ramaekers, Jos Kleijnen, Manuela A Joore, Antoinette D I van Asselt
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 39 (2) (2020)
Anne van Gils, Denise J C Hanssen, Antoinette D I van Asselt, Huibert Burger, Judith G M Rosmalen
Personalized, Web-Based, Guided Self-Help for Patients With Medically Unexplained Symptoms in Primary Care: Protocol for a Randomized Controlled Trial. JMIR research protocols 8 (10) (2019)
Antoinette D I van Asselt, Bram L T Ramaekers, Isaac Corro Ramos, Manuela Joore, Maiwenn Al, Ivonne Lesman-Leegte, Maarten Postma, Pepijn Vemer, Talitha L Feenstra
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. PharmacoEconomics 36 (1) (2019)
Marla Woolderink, Jill A P M Bindels, Silvia M A A Evers, Aggie T G Paulus, Antoinette D I van Asselt, Onno C P Van Schayck
An Online Health Prevention Intervention for Youth with Addicted or Mentally Ill Parents: Experiences and Perspectives of Participants and Providers from a Randomized Controlled Trial. Journal of medical Internet research 17 (12) (2015)